Journal of Cardiac Failure
Volume 14, Issue 1 , Pages 61-74 , February 2008

Cytokines and Myocardial Dysfunction: State of the Art

  • Ayman A. El-Menyar, MBchB, MSc, FRCP

      Affiliations

    • Corresponding Author InformationReprint requests: Ayman Ahmed ElMenyar, MBBCH, MSc, MRCP (UK), Weill Cornell Faculty of Medicine, Doha, Qatar & Department of Cardiology and Cardiovascular Surgery, Hamad General Hospital, PO Box 3050, Doha, State of Qatar.

Received 8 August 2007 ,Revised 7 September 2007 ,Accepted 10 September 2007.

References 

  1. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301–314
  2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol. 1996;14:397–440
  3. Mann DL. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev. 2001;6:71–80
  4. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–711
  5. Mehra VC, Ramgolam VS, Bender JR. Cytokines and cardiovascular disease. J Leukoc Biol. 2005;78:805–818
  6. Prabhu S. Cytokine-modulation of cardiac function. Circ Res. 2004;95:1140–1153
  7. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90:464–470
  8. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol. 2005;95:3C–8C
  9. Mann DL. Inflammatory mediators and the failing heart. Past, present, and the foreseeable future. Circ Res. 2002;91:988–998
  10. Huber-Lang MS, Younkin EM, Sarma JV, et al. Complement-induced impairment of innate immunity during sepsis. J Immunol. 2002;169:3223
  11. Riedemann NC, Guo RF, Neff TA, et al. Increased C5a receptor expression in sepsis. J Clin Invest. 2002;110:101
  12. Piagnerelli M, Boudjeltia KZ, Vanhaeverbeek M, Vincent JL. Red blood cell rheology in sepsis. Intensive Care Med. 2003;29:1052
  13. Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28:964–971
  14. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060–3067
  15. Aukrust P, Gullestad L, Ueland T, Dama JK, Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med. 2005;37:74–85
  16. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without a prior myocardial infarction: the Framingham Study. Circulation. 2003;107:1486–1491
  17. Joulin O, Petillot P, Labalette M, et al. Cytokine profile of human septic shock serum inducing cardiomyocyte contractile dysfunction. Physiol Res. 2007;56:291–297
  18. Adamy C, Le Corvoisier P, Candiani G, et al. Tumor necrosis factor alpha and glutathione interplay in chronic heart failure. Arch Mal Coeur Vaiss. 2005;98:906–912
  19. Amadou A, Nawrocki A, Best-Belpomme M, et al. Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes. Am J Physiol Cell Physiol. 2002;282:C1339–C1347
  20. Cailleret M, Amadou A, Andrieu-Abadie N, et al. N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes. Circulation. 2004;109:406–411
  21. Pathan N, Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004;363:203–209
  22. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201–1206
  23. Bozkurt B, Kribbs S, Clubb FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382–1391
  24. Eriksson SV, Kjekshus J, Eneroth P, Swedberg K. Neopterin, tumor necrosis factor, C-reactive and prostaglandin E2 in patients with severe congestive heart failure treated with enalapril. Circulation. 2000;96(suppl I):I–322. [abstract]
  25. Gullestad L, Aukrust P, Ueland T, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 1999;34:2061–2067
  26. Gurlek A, Kilickap M, Dincer I, Dandachi R, Tutkak H, Oral D. Effect of losartan on circulating TNF-α levels and left ventricular systolic performance in patients with heart failure. J Cardiovasc Risk. 2001;8:279–282
  27. Tsutamoto T, Wada A, Matsumoto T, et al. Relationship between tumor necrosis factor–alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:2086–2092
  28. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1b modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest. 1995;96:1093–1099
  29. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81:627–635
  30. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2:243–249
  31. Eddy LJ, Goeddel DV, Wong GH. Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun. 1992;184:1056–1059
  32. Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science. 1988;242:941–944
  33. Nakano M, Knowlton AA, Yokoyama T, et al. Tumor necrosis factor-induced expression of heat shock protein 72 in adult feline cardiac myocytes. Am J Physiol. 1996;270:H1231–H1239
  34. Plumier JC, Ross BM, Currie RW, et al. Transgenic mice expressing the human heat shock protein 70 have improved post-ischemic myocardial recovery. J Clin Invest. 1995;95:1854–1860
  35. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055–2059
  36. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487–1493
  37. Torre-Amione G, Bozkurt B, Deswal A, Mann DL. An overview of tumour necrosis factor a and the failing human heart. Curr Opin Cardiol. 1999;14:206–210
  38. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000;35:537–544
  39. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986;163:1433–1450
  40. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95:1247–1252
  41. Nakano M, Knowlton AA, Dibbs Z, Mann DL. Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation. 1998;97:1392–1400
  42. Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 1998;97:1375–1381
  43. Nagueh SF, Stetson SJ, Lakkis NM, et al. Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation. 2001;103:1844–1850
  44. Kapadia SR, Yakoob K, Nader S, Thomas JD, Mann DL, Griffin BP. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol. 2000;36:208–212
  45. Sacher RA for the IVIG Advisory Panel. Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol. 2001;108(suppl):S139–S146
  46. Yokoyama T, Nakano M, Bednarczyk JL, et al. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95:1247–1252
  47. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854–2865
  48. Murray DR, Freeman GL. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res. 1996;78:154–160
  49. Gulick T, Chung M, Pieper SJ, et al. Interleukin1 and tumor necrosis factor inhibit cardiac myocytes beta-adrenergic responsiveness. Proc Natl Acad Sci U S A. 1989;86:6753–6757
  50. Panas D, Khadour FH, Szabo C, Schulz R. Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am J Physiol. 1998;275:H1016–H1023
  51. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387–389
  52. Dibbs Z, Thornby J, White BG, et al. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol. 1999;33:1935–1942
  53. Kapadia S, Torre-Amione G, Mann DL. Pitfalls in measuring cytokines. Ann Intern Med. 1994;121:149–150
  54. Kumar A, Haery C, Parrillo JE. Myocardial dysfunction in septic shock. Crit Care Clin. 2000;16:251–287
  55. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest. 1985;76:1539–1553
  56. Kumar A, Wood K, Parrillo JE. Circulating substances and energy metabolism in septic shock. Crit Care Med. 2003;31:632–633
  57. Cain BS, Meldrum DR, Dinarello CA, et al. Tumor necrosis factor-α and interleukin-1β synergistically depress human myocardial function. Crit Care Med. 1999;27:1309–1318
  58. El-Menyar AA. The resuscitation outcome: revisit the story of the stony heart. Chest. 2005;128:2835–2846
  59. El-Menyar Ayman. Pathophysiology and hemodynamic of postresuscitation syndrome. Saudi Med J. 2006;27:441–445
  60. Sharma HS, Das DK. Role of cytokines in myocardial ischemia and reperfusion. Mediators Inflamm. 1997;6:175–183
  61. Niemann JT, Garner Daniel, Lewis RJ. Tumor necrosis factor-alpha is associated with early postresuscitation myocardial dysfunction. Crit Care Med. 2004;32:1753–1758
  62. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995;92:1479–1486
  63. Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:376–382
  64. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133–3140
  65. Meldrum DR, Dinarello CA, Shames BD, et al. Ischemic preconditioning decreases postischemic myocardial tumor necrosis factor-alpha production: potential ultimate effector mechanism of preconditioning. Circulation. 1998;98(suppl II):II-214–18
  66. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20:683–693
  67. Van Deventer SJH, Buller HR, Ten Cate JW, et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood. 1990;76:2520–2526
  68. Ng SB, Tan YN, Guy GR. Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1. J Biol Chem. 1994;269:19021–19027
  69. Sanceau J, Kaisho T, Hirano T, Wietzerbin J. Triggering of the human interleukin-6 gene by interferon-g and tumor necrosis factor-α in monocyte cells involves cooperation between interferon regulatory factor-1, NFkB, and SP1 transcription factors. J Biol Chem. 1995;270:27920–27931
  70. Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med. 1990;7:147–159
  71. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621–636
  72. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:391–398
  73. Mohler ER, Sorensen LC, Ghali JK, et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial: Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol. 1997;30:35–41
  74. Sugishita K, Kinugawa K, Shimizu T, et al. Cellular basis for the acute inhibitory effects of IL-6 and TNF on excitation-contraction coupling. J Mol Cell Cardiol. 1999;31:1457–1467
  75. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1587
  76. Adrie C, Adib-Conquy M, Laurent I, et al. Successful cardiopulmonary resuscitation after cardiac arrest as a “sepsis-like” syndrome. Circulation. 2002;106:562–568
  77. Kinugawa K, Takahashi T, Kohmoto O, et al. Nitric oxide-mediated effects of interleukin-6 on [Ca2+]i and cell contraction in cultured chick ventricular myocytes. Circ Res. 1994;75:285–295
  78. Geppert A, Steiner A, Zorn G, et al. Multiorgan failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med. 2002;30:1987–1994
  79. Rao KM. Molecular mechanisms regulating iNOS expression in various cell types. J Toxicol Environ Health B Crit Rev. 2000;3:27–58
  80. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387–389
  81. Bolger AP, Sharma R, von Haehling S, et al. Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure. Am J Cardiol. 2002;90:384–389
  82. Nishio R, Matsumori A, Shioi T, Ishida H, Sasayama S. Treatment of experimental viral myocarditis with interleukin-10. Circulation. 1999;100:1102–1108
  83. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103:220–225
  84. Kaur K, Sharma AK, Singal PK. Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291:H106–H113
  85. Nishii M, Inomata T, Takehana H, et al. Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol. 2004;44:1292–1297
  86. Damås JK, Eiken HG, Oie E, et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res. 2000;47:778–787
  87. Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. 1998;97:1136–1143
  88. Damas JK, Gullestad L, Ueland T, et al. CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc Res. 2000;45:428–436
  89. Damas JK, Gullestad L, Aass H, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure–modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol. 2001;38:187–193
  90. Vadlamani L, Abraham WT. Insights into pathogenesis and treatment of cytokines in cardiomyopathy. Curr Cardiol Rep. 2000;2:120–128
  91. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation. 1994;89:1580–1586
  92. Galtius-Jensen S, Wroblewski H, Emmeluth C, et al. Plasma endothelin in congestive heart failure: a predictor of cardiac death?. J Card Fail. 1996;2:71–76
  93. McMurray JJ, Ray SG, Abdullah I, et al. Plasma endothelin in chronic heart failure. Circulation. 1992;85:1374–1379
  94. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428
  95. Alonso-Martínez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, González-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail. 2002;4:331–336
  96. Birks EJ, Owen VJ, Burton PB, et al. Tumor necrosis factor-alpha is expressed in donor heart and predicts right ventricular failure after human heart transplantation. Circulation. 2000;102:326–331
  97. Tatli E, Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol. 2005;21:344–348
  98. Gullestad L, Ueland T, Brunsvig A, et al. Effect of metoprolol on cytokine levels in chronic heart failure—a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am Heart J. 2001;141:418–421
  99. Ohtsuka T, Hamada M, Saeki H, et al. Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;89:996–999
  100. Lappegard KT, Bjornstad H. Anti-inflammatory effect of cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2006;29:753–758
  101. Mann DL. Cytokines as mediators of disease progression in the failing heart. In:  Hosenpud JD,  Greenberg BH editor. Congestive heart failure. Philadelphia: Lippincott Williams & Wilkins; 1999;p. 212–232
  102. Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95(suppl):9C–16C
  103. Yoshimura T, Kurita C, Nagoa T, et al. Inhibition of tumor necrosis factor-alpha and interleukin-1 beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology. 1997;54:144–152
  104. Szabo C, Hasko G, Zingarelli B, et al. Isoproterenol regulates tumor necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxemia. Immunology. 1997;90:95–100
  105. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1994;89:955–958
  106. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 1998;351:1091–1093
  107. Zabel P, Wolter DT, Schonharting MM, Schade UF. Oxpentifylline in endotoxaemia. Lancet. 1989;23:1474–1477
  108. Bergman MR, Holycross BJ. Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors. J Pharmacol Exp Ther. 1996;279:247–254
  109. Feldman AM, McNamara DM, Wagner DR. AMPD1 gene mutation in congestive heart failure: new insights into the pathobiology of disease progression. Circulation. 1998;99:1397–1399
  110. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells. A possible mechanism for its effect in heart failure. Circulation. 1997;96:1386–1389
  111. Matsumori A, Ono K, Nishio R, et al. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation. 1997;96:1501–1506
  112. Ammann P, Rizzoli R, Bonjour JP. Transgenic mice expressing soluble tumor necrosis factor are protected against bone loss caused by estrogen deficiency. J Clin Invest. 1997;99:1699–1703
  113. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711–2719
  114. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–1135
  115. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108:839–843
  116. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis. 2005;178:359–363
  117. Oi S, Haneda T, Osaki J, et al. Lovastatin prevents angiotensin II–induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol. 1999;376:139–148
  118. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1671–1678
  119. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart. 2005;91:27–31
  120. Strey CH, Young JM, Molyneux SL, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis. 2005;179:201–206
  121. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–259
  122. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390
  123. Kapadia S, Torre-Amione G, Yokoyama T, et al. Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNF in vitro. Am J Physiol. 1995;37:H517–H525
  124. Deswal A, Bozkurt B, Seta Y, et al. A phase I trial of tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc) in patients with advanced heart failure. Circulation. 1999;99:3224–3226
  125. Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted ant-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103:1044–1047
  126. Mann DL, McMurray JJ, Packer M, et al. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594–1602
  127. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002;86:123
  128. US Food and Drug Administration. Update on the TNF-a blocking agents. Available at: www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm. Accessed March 3, 2003.
  129. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807–811
  130. Sarzi-Puttini P, Atzeni F, Doria A, Iaccarino L, Turie M. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus. 2005;14:780–784
  131. Sugamori T, Ishibashi Y, Shimada T, et al. Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cardiomyopathy: close correlation of tumor necrosis factor-alpha with systemic and local production of nitric oxide. Circ J. 2002;66:627–632
  132. Kurrelmeyer KM, Michael LH, Baumgarten G, et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A. 2000;97:5456–5461
  133. Packer M. Role of the sympathetic nervous system in chronic heart failure: a historical and philosophical perspective. Circulation. 1990;82(Suppl):I1–I6
  134. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-a rheumatoid arthritis and heart failure: a rheumatological dilemma. Autoimmun Rev. 2005;4:153–161
  135. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?. Arthritis Rheum. 2004;50:1040–1050
  136. von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart—pathophysiology and therapeutic implications. Basic Res Cardiol. 2004;99:18–28
  137. von Haehling S, Anker SD. Future prospects of anticytokine therapy in chronic heart failure. Expert Opin Investig Drugs. 2005;14:163–176
  138. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol. 1995;155:5038–5045
  139. Kubota T, McNamara DM, Wang JJ, et al. Effects of tumour necrosis factor gene polymorphisms on patients with congestive heart failure. VEST investigators for TNF-genotype-analysis. Vesnarinone Survival Trial. Circulation. 1998;97:2499–2501
  140. Kadokami T, McTiernan CF, Frye CS, et al. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest. 2000;106:589–597
  141. Staudt A, Landsberger M, Staudt Y, Felix SB. Cytokines-Causes, players, or by standers in heart failure. Herz. 2002;27:691–698
  142. Feldman AM, McTiernan C. Is there any future for tumor necrosis factor antagonists in chronic heart failure?. Am J Cardiovasc Drugs. 2004;4:11–19
  143. Clark MA, Plank LD, Connolly AB, et al. Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis: a randomized, clinical trial. Crit Care Med. 1998;26:1650–1659
  144. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251–259
  145. Opal SM, Cross AS, Kelly NM, et al. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis. 1990;161:1148–1152
  146. Kojouharoff G, Hans W, Obermeier F, et al. Neutralization of tumor necrosis factor (TNF), but not of IL-1, reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol. 1997;107:353–358
  147. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254–2259
  148. Muller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000;101:385–391
  149. Bolton AE. Biologic effects and basic science of a novel immune-modulation therapy. Am J Cardiol. 2005;95(suppl):24C–29C
  150. Torre-Amione G, Bourge RC, Colucci WS, et al. ACCLAIM Investigators. A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design. Can J Cardiol. 2007;23:369–376
  151. ACCLAIM: Immune-modulation therapy fails to meet primary end point in CHF study. Available at: http://www.theheart.org/article/718941.do and http://clinicaltrials.gov/ct/show/NCT00111969?order=2. Accessed August 29, 2007.
  152. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor: therapy and heart failure. What have we learned and where do we go from here?. Arthritis Rheum. 2004;50:1040–1050
  153. Kadokami T, Frye C, Lemster B, et al. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation. 2001;104:1094–1097
  154. Kubota T, Bounoutas GS, Miyagishima M, et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation. 2000;101:2518–2525

PII: S1071-9164(07)01070-6

doi: 10.1016/j.cardfail.2007.09.006

Journal of Cardiac Failure
Volume 14, Issue 1 , Pages 61-74 , February 2008

Article Tools

* Image Usage & Resolution